Georgios Kotronis

Georgios Kotronis

Auto-generated profile, based on publicly available information

Georgios Kotronis

Aghios Pavlos Gen Hosp, Dept Internal Med, Thessaloniki, Greece

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Metabolism
Verified
Journal Article
Closed access
Michael DoulberisMichael Doulberis
Michael Doulberis
GKGeorgios Kotronis
Georgios Kotronis
DGDimitra Gialamprinou
Dimitra Gialamprinou
JKJannis Kountouras
Jannis Kountouras
PKPanagiotis Katsinelos
Panagiotis Katsinelos

23 October 2019 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
APApostolis Papaefthymiou
Apostolis Papaefthymiou
Michael DoulberisMichael Doulberis
Michael Doulberis
PKPanagiotis Katsinelos
Panagiotis Katsinelos
CLChristos Liatsos
Christos Liatsos
SPStergios A Polyzos
Stergios A Polyzos
JKJannis Kountouras
Jannis Kountouras

9 March 2021 in Medicina
Verified
Journal Article
Open access
PDF file
Michael DoulberisMichael Doulberis
Michael Doulberis
APApostolis Papaefthymiou
Apostolis Papaefthymiou
GKGeorgios Kotronis
Georgios Kotronis
DGDimitra Gialamprinou
Dimitra Gialamprinou
Elpidoforos Soterakis SoteriadesElpidoforos Soterakis Soteriades
Elpidoforos Soterakis Soteriades
JKJannis Kountouras
Jannis Kountouras
The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic warrants an imperative necessity for effective and safe vaccination, to restrain Coronavirus disease 2019 (COVID-19) including transmissibility, morbidity, and mortality. In this regard, intensive medical and biological research leading to the development of an arsenal of vaccines, albeit incomplete preconditioned evaluation, due to emergency. The subsequent scientific gap raises some concerns in the medical community and the general public. More specifically, the accelerated vaccine development downgraded the value of necessary pre-clinical studies to elicit medium- and long-term beneficial or harmful consequences. Previous experience and pathophysiological background of coronaviruses’ infections and vaccine technologies, combined with the global vaccines’ application, underlined the obligation of a cautious and qualitative approach, to illuminate potential vaccination-related adverse events. Moreover, the high SARS-CoV-2 mutation potential and the already aggregated genetical alterations provoke a rational vagueness and uncertainty concerning vaccines’ efficacy against dominant strains and the respective clinical immunity. This review critically summarizes existing evidence and queries regarding SARS-CoV-2 vaccines, to motivate scientists’ and clinicians’ interest for an optimal, individualized, and holistic management of this unprecedented pandemic.

17 February 2022 in Medicina
Verified
Journal Article
Open access
PDF file
JKJannis Kountouras
Jannis Kountouras
DGDimitra Gialamprinou
Dimitra Gialamprinou
GKGeorgios Kotronis
Georgios Kotronis
APApostolis Papaefthymiou
Apostolis Papaefthymiou
EEEleftheria C. Economidou
Eleftheria C. Economidou
Michael DoulberisMichael Doulberis
Michael Doulberis
The persistence of the coronavirus disease 2019 (COVID-19) pandemic has triggered research into limiting transmission, morbidity and mortality, thus warranting a comprehensive approach to guide balanced healthcare policies with respect to people’s physical and mental health. The mainstay priority during COVID-19 is to achieve widespread immunity, which could be established through natural contact or vaccination. Deep knowledge of the immune response combined with recent specific data indicates the potential inferiority of induced immunity against infection. Moreover, the prevention of transmission has been founded on general non-pharmacological measures of protection, albeit debate exists considering their efficacy and, among other issues, their socio-psychological burden. The second line of defense is engaged after infection and is supported by a plethora of studied agents, such as antibiotics, steroids and non-steroid anti-inflammatory drugs, antiviral medications and other biological agents that have been proposed, though variability in terms of benefits and adverse events has not allowed distinct solutions, albeit certain treatments might have a role in prevention and/or treatment of the disease. This narrative review summarizes the existing literature on the advantages and weaknesses of current COVID-19 management measures, thus underlining the necessity of acting based on the classical principle of “ofeleein i mi vlaptin”, that is, to help or not to harm.

20 June 2024 in Cureus
Verified
Journal Article
Open access
PIPanagiota Issa
Panagiota Issa
DADimitrios Agapakis
Dimitrios Agapakis
KMKonstantina Machaira
Konstantina Machaira
KIKarageorgiou Ioannis
Karageorgiou Ioannis
GKGeorgios Kotronis
Georgios Kotronis
Acute pancreatitis has been considered a rare potential adverse effect of sodium-glucose co-transporter2 inhibitors (SGLT-2is), a new class of medications recently approved for use as an add-on therapy in patients with poorly controlled type 2 diabetes mellitus as well as in individuals with heart failure (HF) and chronic kidney disease (CKD). SGLT-2i can effectively reduce cardiovascular mortality and the deterioration of renal function. There are only a few published cases of acute pancreatitis linked to SGLT-2i administration. Our case describes a 58-year-old male who presented to the emergency department with a clinical presentation of acute pancreatitis, with no known risk factors, who was recently started on therapy with dapagliflozin. Following thorough clinical and laboratory testing, the diagnosis of pancreatitis was associated with dapagliflozin. Upon discharge, dapagliflozin was discontinued with no further recurrence of epigastric pain.

9 December 2022 in Cureus
Verified
Journal Article
Open access
GDGEORGE DIVIDIS
GEORGE DIVIDIS
GPGeorgios Evaggelos Papadopoulos
Georgios Evaggelos Papadopoulos
IKIoannis Karageorgiou
Ioannis Karageorgiou
GKGeorgios Kotronis
Georgios Kotronis
Remdesivir is an antiviral agent used as supportive care in adults with SARS-COV2-induced pneumonia. We report a case of an 81-year-old patient who developed hepatocellular acute liver injury 48 hours after initiating remdesivir. During the investigation, other causes of hepatotoxicity were excluded. A decrease in transaminases and international normalized ratio (INR) was observed 24 hours after cessation of remdesivir. An abdominal CT demonstrated hepatic congestion, retrograde hepatic venous opacification shortly after intravenous contrast injection, and dilatation of hepatic veins and inferior vena cava. We suggest congestive hepatopathy secondary to remdesivir as a possible component of liver injury.